PCSK9 polypeptides

Details PCSK9 polypeptides PCSK9 polypeptides

2009-06-23

2010-12-07

Fronda, Christian L (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S183000, C435S252300, C435S320100, C536S023100, C536S023200

Reexamination Certificate

active

07846706

ABSTRACT:
The present invention provides novel polynucleotides encoding PCSK9b and PCSK9c polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel PCSK9b and PCSK9c polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

REFERENCES:
patent: 7129338 (2006-10-01), Ota et al.
patent: 7300754 (2007-11-01), Abi Fadel et al.
patent: 2003/0119038 (2003-06-01), Bingham et al.
patent: 2004/0023243 (2004-02-01), Henry et al.
patent: 2004/0038242 (2004-02-01), Edmonds et al.
patent: 2004/0248177 (2004-12-01), Fadel et al.
patent: 2005/0101529 (2005-05-01), Yue et al.
patent: 2006/0068428 (2006-03-01), Vance et al.
patent: 2006/0147945 (2006-07-01), Edmonds et al.
patent: 2006/0223088 (2006-10-01), Rosen et al.
patent: 2006/0223090 (2006-10-01), Rosen et al.
patent: 2007/0015696 (2007-01-01), Rosen et al.
patent: 2007/0037206 (2007-02-01), Rosen et al.
patent: 1 403 282 (2004-03-01), None
patent: 2002017376 (2002-01-01), None
patent: 2002017376 (2002-01-01), None
patent: 2003512840 (2003-04-01), None
patent: 2005130764 (2005-05-01), None
patent: WO01/31007 (2001-05-01), None
patent: WO01/57081 (2001-08-01), None
patent: WO01/98468 (2001-12-01), None
patent: WO02/46383 (2002-06-01), None
patent: WO02/090526 (2002-11-01), None
patent: WO02/012993 (2002-12-01), None
patent: WO02/012994 (2002-12-01), None
patent: WO2004/097047 (2004-11-01), None
patent: WO 2007030937 (2007-03-01), None
patent: WO 2007128121 (2007-11-01), None
Seidah et al. Int J Biochem Cell Biol. 2008;40(6-7):1111-25. Epub Feb. 8, 2008.
Seidah, et a., Int. J. Biochem. Cell Biol., 2008, 40 (6-7): 1111-1125, Epub Feb. 8, 2008.
Abifadel, et al., “Mutations in PCSK9 cause autosomal dominant hypercholesterolemia”, Nature Genetics, vol. 34(2), pp. 154-156 (2003).
Attie, Alan, D., “The Mystery of PCSK9”, Arterioscler. Thromb. Vasc. Biol., vol. 24, pp. 1337-1339 (2004).
Austin, et al., “Risk Factors For Coronary Heart Disease In Adult Female Twins”, Amer. J. Epidemiology, vol. 125(2), pp. 308-318 (1987).
Benjannet, et al., “NARC-1/PCSK9 and Its Natural Mutants”, J. Biol. Chem., vol. 279(47), pp. 48865-48875 (2004).
Berge, et al., “Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy”, Arterioscler. Thromb. Vasc. Biol., vol. 26, pp. 1094-1100 (2006).
Brown, et al., “A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood”, PNAS, vol. 96, pp. 11041-11048 (1999).
Cohen, et al., “Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9”, Nature Genetics, vol. 37(2), pp. 161-165 2005).
Desai, et al., “Nell1-deficient mice have reduced expression of extracellular matrix proteins causing cranial and vertebral defects”, Human. Molec. Genetics, vol. 15(8), pp. 1329-1341 (2006).
Dubuc, et al., “Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia”, Arterioscler. Thromb. Vasc. Biol., vol. 24, pp. 1454-1459 (2004).
Fredrickson, et al., “Fat Transport in Lipoproteins—An Integrated Approach to Mechanisms And Disorders (Concluded)”, New Eng. J. Medicine, vol. 276(5), pp. 273-281 (1967).
Goldstein, et al., “Familial Hypercholesterolemia: Pathogenesis of a Receptor Disease”, Johns Hopkins Med. J., vol. 143, pp. 8-16 (1978).
Graham, et al., “Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice”, J. Lipid Res., vol. 48, pp. 763-767 (2007).
Hallman, et al., Relation of PCSK9 Mutations to Serum Low-Density Lipoprotein Cholesterol in Childhood and Adulthood (from the Bogalusa Heart Study), Am. J. Cardiol., vol. 100, pp. 69-72 (2007).
Horton, et al., “Molecular biology of PCSK9: its role in LDL metabolism”, TIBS, vol. 32(2), vol. 32(2), pp. 71-77 (2007).
Houghten, et al., “Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery”, Nature, vol. 354, pp. 84-86 (1991).
Hunt, et al., “Genetic Localization to Chromosome 1p32 of the Third Locus for Familial Hypercholesterolemia in a Utah Kindred”, Arterioscler. Thromb. Vasc. Biol., vol. 20, pp. 1089-1093 (2000).
Innerarity, et al., “Familial defective apolipoprotein B-100: Low density lipoproteins with abnormal receptor binding”, PNAS, vol. 84, pp. 6919-6923 (1987).
Khachadurian, Avedis, K., “The Inheritance of Essential Familial Hypercholesterolemia”, American J. Med., vol. 37, pp. 402-407 (1964).
Lagace, et al., “Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice”, J. Clin. Invest., vol. 116(11), pp. 2995-3005 (2006).
Lalanne, et al., “Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells”, J. Lipid Res., vol. 46, pp. 1312-1319 (2005).
Lam, et al., “A new type of synthetic peptide library for identifying ligand-binding activity”, Nature, vol. 354, pp. 82-84 (1991).
Lambert, Gilles, “Unravelling the functional significance of PCSK9”, Curr. Opin. Lipidol., vol. 18, pp. 304-309 (2007).
Lambert, et al., “Fasting Induces Hyperlipidemia in Mice Overexpressing Proprotein Convertase Subtilisin Kexin Type 9: Lack of Modulation of Very-Low-Density Lipoprotein Hepatic Output by the Low-Density Lipoprotein Receptor”, Endocrinology, vol. 147(10), pp. 4985-4995 (2006).
Lusis, Aldons, J., “Atherosclerosis”, Nature, 407(6801), pp. 233-241 (2000).
Maxwell, et al., “Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype”, PNAS, vol. 101(18), pp. 7100-7105 (2004).
Maxwell, et al., “Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment”, PNAS, vol. 102(6), pp. 2069-2074 (2005).
Maxwell, et al., “Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice”, J. Lipid Res., vol. 44, pp. 2109-2119 (2003).
Mayne, et al., “Plasma PCSK9 levels correlate with cholesterol in men but not in women”, Biochem. Biophysical Res. Comm., vol. 361, pp. 451-456 (2007).
McNutt, et al., “Catalytic Activity is not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells”, J. Biol. Chem., vol. 282(29), pp. 20799-20803 (2007).
Morganroth, et al., “Pseudohomozygous type II hyperlipoproteinemia”, J. Pediatrics, vol. 85(5), pp. 639-643 (1974).
Naureckiene, et al., “Functional characterization of Narc 1, a novel proteinase related to proteinase K”, Biochem. Biophysics, vol. 420, pp. 55-67 (2003).
Park, et al., “Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver”, J. Biol. Chem., vol. 279(48), pp. 50630-50638 (2004).
Perusse, et al., “Genetic and Environmental Determinants of Serum Lipids and Lipoproteins in French Canadian Families”, Arteriosclerosis, vol. 9, pp. 308-318 (1989).
Piper, et al., “The Crystal Structure of PCSK9: a Regulator of Plasma LDL-Cholesterol”, Structure, vol. 15, pp. 545-552 (2007).
Poirier, et al., “Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous systemȁ

Affiliated with

Also associated with

Rating

PCSK9 polypeptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PCSK9 polypeptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PCSK9 polypeptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4174807